CD2 and neoplasm: Additional mechanisms of AML relapse after CIML NK therapy may be associated with the absence of ligands for CD2, a receptor that is expressed on the NK cell populations after infusion, and that is involved in mediating tumor target cytotoxicity via interaction with CD16 (38).